LIGAND PHARMACEUTICALS INC (LGND) Stock Profile — Insider Trades & Financials

Revenue$59.7M

Net Income$44.8M

EPS$6.13

Market Cap$4.1B

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Todd C. Davis

CEO & Executive Director

Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma (cancer) treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol.

Employees: 68
Headquarters: SAN DIEGO, CA, United States
Website: www.ligand.com

⚡

Core Efficiency

ROE?

4.40%

ROA?

2.87%

D/E Ratio?

0.53

Op. Margin?

23.20%

📊

Profitability Ratios

Net Margin?

75.06%

Loading company sections...

LIGAND PHARMACEUTICALS INC

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness